Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma.

https://escholarship.org/uc/item/00z95359
Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma

K Ueno1, H Hirata1, Y Shahryari1, Y Chen1, MS Zaman1, K Singh1, ZL Tabatabai2, Y Hinoda3 and R Dahiya*,1
1Department of Urology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA; 2Department of Pathology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, CA, USA; 3Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

BACKGROUND: The purpose of this study was to identify new tumour suppressor microRNAs (miRs) in clear cell renal cell carcinoma (ccRCC), carry out functional analysis of their suppressive role and identify their specific target genes.

METHODS: To explore suppressor miRs in RCC, miR microarray and real-time PCR were performed using HK-2 and A-498 cells. Cell viability, invasion and wound healing assays were carried out for functional analysis after miR transfection. To determine target genes of miR, we used messenger RNA (mRNA) microarray and target scan algorithms to identify target oncogenes. A 3’UTR luciferase assay was also performed. Protein expression of target genes in ccRCC tissues was confirmed by immunohistochemistry and was compared with miR-584 expression in ccRCC tissues.

RESULTS: Expression of miR-584 in RCC (A-498 and 769-P) cells was downregulated compared with HK-2 cells. Transfection of miR-584 dramatically decreased cell motility. The ROCK-1 mRNA was inhibited by miR-584 and predicted to be target gene. The miR-584 decreased 3’UTR luciferase activity of ROCK-1 and ROCK-1 protein expression. Low expression of miR-584 in ccRCC tissues was correlated with high expression of ROCK-1 protein. The knockdown of ROCK-1 by siRNA inhibited cell motility.

CONCLUSION: miR-584 is a new tumour suppressor miR in ccRCC and inhibits cell motility through downregulation of ROCK-1.

Keywords: miRNA-584; motility; RCC; ROCK-1

Renal cell carcinoma (RCC) is the tenth leading cause of death, accounting for 2–3% of adult malignancies (Jemal et al, 2008). The 5-year survival of RCC is estimated to be approximately 55% (Pascual and Borque, 2008) and that of metastatic RCC is approximately 10% (Reeves and Liu, 2009). Recently a multikinase inhibitor has been approved for the treatment of advanced RCC (Stadler et al, 2010), but is not globally used. Therefore, new sensitive, reliable tumour markers and effective therapeutic methods are needed for renal cancer. The mouse genome has been estimated to harbour 22000 genes with 181 047 transcripts, however, protein-coding transcripts account for just 16 247 of the total (Carninci et al, 2005). These data show that non-coding RNAs are very numerous and potentially important in gene and protein regulation. These small non-coding RNAs and microRNA (miR) are well known as examples of non-coding RNAs (Ying et al, 2008). The miRs initially bind to the 3’UTR of target gene messenger RNA (mRNA) and repress translation or induce mRNA cleavage (McManus and Sharp, 2002), thereby inhibiting translation from mRNA to protein. Human miRs have been predicted to number approximately 1000 (Berezikov et al, 2005). Aberrant expression of miRs occurs in many types of cancers, some of which function as tumour suppressor genes or oncogenes (Lu et al, 2005; Esquela-Kerscher and Slack, 2006; Volinia et al, 2006). Decreased expression of tumour suppressor miRs results in increased expression of target oncogenes. In contrast, increased expression of oncogenic miRs leads to loss or decreased expression of target tumour suppressor genes. According to previous reports, a number of microRNA microarray studies have been performed in renal cancer patient samples and the expression level of several miRs (miR-17-5p, miR-20a, miR-21, miR-34a, miR-10a, miR-106b, miR-155 and miR-210) were validated by real-time (RT)–PCR and found to be upregulated in renal cancer tissues (Gottardo et al, 2007; Nakada et al, 2008; Huang et al, 2009; Jung et al, 2009; Petillo et al, 2009; Chow et al, 2010; Juan et al, 2010; Slaby et al, 2010; Weng et al, 2010). Some miRs (miR-141 and miR-200c) are downregulated in renal cancer compared with normal kidney tissues (Slaby et al, 2010). However, there have been few reports regarding the detailed functional analysis of these miRs in RCC.

Therefore, the aim of this study was to identify new tumour suppressor miRs that influence renal cancer progression, to validate the function of these tumour suppressor miRs and also to identify their target oncogenes.

In this study, we performed miR microarray analysis and validated microarray data by RT-PCR. Among several potential tumour suppressor miRs, miR-584 was downregulated in kidney...
cancer cell lines and was consistent with the microarray data. Rock-1 was selected on the basis of the microarray analysis and a target scan algorithm as a cell motility-related gene because miR-584 overexpression significantly inhibited cell motility. Therefore, we observed that miR-584 decreased cell motility through inhibition of ROCK-1 in RCC cell lines and the expression of miR-584 was inversely correlated with that of ROCK-1 in ccRCC (clear cell renal cell carcinoma) tissues. These results suggest that miR-584 functions as a new tumour suppressor miR in RCC via ROCK-1 knockdown.

MATERIALS AND METHODS

Cell lines and cell cultures

A-498 and 769-P cells originated from clear renal cell adenocarcinoma, and we selected them as model RCC cells. The HK-2 cells are derived from normal kidney and were used as control cells. The miR-584 expression level in A-498 and 769-P cells was lower than HK-2 cells, which was consistent with the finding that miR-584 expression in tumour tissue samples was lower compared with normal samples. In addition, A-498 and 769-P cells were used for functional studies of miR-584. The HK-2 cells were cultured in keratinocyte-SFM (Gibco/Invitrogen, Carlsbad, CA, USA). A-498 and 769-P cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum.

RNA extraction

MiR and total RNA were extracted from cell lines using a miRNasey Mini Kit and a RNasey Mini Kit (Qiagen, Valencia, CA, USA). The miRs from clinical samples were extracted using laser-capture-micro-dissection techniques with a miRNasey FFPE Kit (Qiagen).

Microarray (miR and mRNA microarray)

For microRNA microarray, total RNA was extracted from HK-2 and A-498 cells using a miRNasey Mini Kit. The miR microarray analysis was carried out and analysed by LC Science, LLC (Houston, TX, USA). We decided on candidate miR-584 for further experiments on the basis of the LC science microarray data. In order to find potential target oncogenes of tumour suppressive miR-584, we used an mRNA microarray service (Phalanx Bio Inc., Palo Alto, CA, USA). Namely, renal cancer cells (A-498 cells) were transfected with negative control or miR-584. Total RNA was extracted (miR-NC and miR-584 over-expression) after 72 h and Phalanx Bio Inc. performed mRNA microarray using the extracted RNA. On the basis of the microarray data, we identified several target oncogenes.

Clinical samples

In total, 14 pairs of RCC and their normal adjacent tissues in paraffin blocks were obtained from NDRI (six pairs) (Philadelphia, PA, USA) and the Pathology Department of the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veterans Affairs Medical Center at San Francisco (eight pairs). Informed consent was obtained from eight patients from the Veter
inserts was about 200 and 100 bp confirmed by electrophoresis after the NotI sequence was incorporated into primers. Vectors were sequenced directly by an outside vendor (MCLAB, South San Francisco, CA, USA). For 3′UTR luciferase assay, A-498 cells were co-transfected with Negative Control or hsa-miR-584 and pmirGLO Dual-Luciferase miRNA Target Expression Vectors using Lipofectamine 2000 (Invitrogen). Luciferase assay was performed using the Dual-Luciferase Reporter Assay System (Promega) at 48 h after transfection.

Quantitative RT-PCR

Extracted total RNA was reverse-transcribed into single-stranded cDNA using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) and a TaqMan microRNA reverse transcription kit (Applied Biosystems). The RT-PCR was performed using first-strand cDNA with TaqMan Fast Universal PCR Master Mix (Applied Biosystems). The assay numbers for the mRNA endogenous control (β-actin), target gene, miR endogenous control (RNU48) and target miRs were as follows: β-actin (HS99999903_m1), ROCK-1 (HS00178463_m1), RNU48 (001006) and miR-584 (001624). Quantitative PCR was performed on an Applied Biosystems Prism 7500 Fast Sequence Detection System (Applied Biosystems). Quantitative PCR parameters for cycling were as follows: 95°C for 20 s, 40 cycles of PCR at 95°C for 1 s, and 60°C for 30 s. All reactions were done in a 10-μl reaction volume in triplicate. The mRNA and miR expression level were determined using the 2-ΔΔCt method.

Western analysis

At 72 h after transfection, cells were washed in ice-cold PBS and added to RIPA lysis and extraction buffer (Fisher Scientific) containing Protease Inhibitor Cocktail I (Millipore, Billerica, MA, USA). Dishes were incubated for 15 min on ice and cells were collected with a cell lifter and rotated for 30 min at 4°C followed by centrifugation at 14,000 r.p.m. for 10 min at 4°C. Total protein was analysed by western blotting using primary antibodies, followed by anti-mouse and anti-rabbit IgG HRP-conjugated secondary antibodies (Cell Signaling Technology, Beverly, MA, USA), and were visualised with LumiGLO Reagent and peroxide reagent (Cell Signaling Technology). The primary antibodies used were anti-ROCK1 Antibody (BD Biosciences # 611136) and anti-beta-actin (Cell Signaling Technology #3700) antibodies.

Immunohistochemistry (IHC)

In total, 14 paraffin-embedded specimens were used for IHC. Antigen retrieval was carried out by microwaving in citrate buffer (Thermo Scientific, Waltham, MA, USA). Slides were incubated overnight with anti-ROCK-1 antibody (# ab45171, Abcam, Cambridge, MA, USA). The Thermo Scientific Lab Vision Ultra Vision Detection System (Thermo Scientific, Waltham, MA, USA) was used as a chromogen. Typical immunohistochemical findings of ROCK-1 are shown.

Knockdown of ROCK-1 mRNA

Renal cancer cells were transfected with ROCK-1 siRNAs (si-ROCK-1 (HSS109292)), Invitrogen) or negative control siRNA (si-NC, Invitrogen) using Lipofectamine 2000 according to the manufacturer’s instructions. The siRNAs sequences are as follows; ROCK-1 siRNA sequence, 5′-UGAUCCUGUGAGCCUGCCGCAUGUGUC-3′.

Statistical analysis

All statistical analyses were performed using GraphPad prism 5 software (GraphPad Software, San Diego, CA, USA). A P-value of <0.05 was regarded as statistically significant.

RESULTS

Expression level of miR-584 in cell lines and primary tissues

To identify tumour suppressor miR in RCC, we screened a miRNA microarray using normal kidney HK-2 cells and RCC A-498 cells. To confirm miR-584 expression, we performed RT-PCR and found that miR-584 expression in renal cancer cells (A-498 and 769-P) was significantly lower than that in HK-2 (Figure 1A). To analyse miR-584 expression in clinical samples, total RNA was extracted from 14 pairs of RCC and their adjacent normal FFPE tissues and RT-PCR was performed. As consistent with the results in cell lines, the miR-584 expression was significantly lower in renal cancer tissues (9/14, 64%) than in normal tissues (Table 1).

Evaluation of functional effects of miR-584 on A-498 and 769-P cells

To analyse the function of miR-584 in RCC, miR-584 and miR control were transiently transfected into A-498 and 769-P cells. The expression level of miR-584 was significantly increased at 72 h after transfection (Figure 1B). Cell viability was decreased in miR-584 transfectants compared with controls at 6 days after transfection (Figure 1C). Cell motility was also significantly decreased in miR-584-transfected renal cancer cells (Figure 2A and B).

Evaluation of target genes of miR-584

To identify the target genes of miR-584, we initially used mRNA microarray to compare the expression level between miR-584-transfected A-498 cells and miR controls (data not shown). Second, we searched for target oncogenes of tumour suppressor miR-584 on the basis of the target scan algorithms (microRNA org. and TargetScanHuman 5.1) and selected the target oncogene, ROCK-1. To assay the inhibitory effect of miR-584 on ROCK-1 gene transcription, 3′UTR luciferase assay was performed with A-498 cells. The luciferase activity in miR-584-transfected cells was decreased to about 80% of that compared with miR control (Figure 3B). To examine the inhibitory effect of miR-584 on protein level, we did western analysis at 72 h after miR-584 transfection into A-498 and 769-P cells. We observed that protein levels of ROCK-1 in miR-584-transfected A-498 and 769-P cells were significantly decreased compared with miR control (Figure 3C).

Relationship between tumour suppressor miR-584 expression and target oncogene ROCK-1 protein expression levels in renal cancer tissues

To compare the relationship between miR-584 and ROCK-1 expression in renal cancer tissues, the expression level of ROCK-1 protein in 14 primary ccRCC tissues were examined by IHC. Typical immunohistochemical findings of ROCK-1 are shown in Figure 4A. The expression level of ROCK-1 was assessed with an IHC score and compared with that of miR-584 (Figure 4B). The ROCK-1 protein expression was significantly higher in ccRCC cases with lower miR-584 expression than in those with higher miR-584 expression (Figure 4C).

Evaluation of the effects of ROCK-1 knockdown on A-498 and 769-P cell motility

To analyse whether ROCK-1 affects cell motility of A-498 and 769-P cells, ROCK-1 siRNA (si-ROCK1) and control siRNA (si-NC) were transfected into A-498 and 769-P cells. The ROCK-1 mRNA was analysed using RT-PCR at 48 h after transfection. The ROCK-1 mRNA was significantly decreased in si-ROCK-1-transfected A-498 and 769-P cells (Figure 5A). Knockdown of ROCK-1 protein
**DISCUSSION**

There have been several miR studies related to renal cancer and these reports have initially dealt with miR profiling expression was also confirmed by western blot analysis (Figure 5B). To look at whether ROCK-1 knockdown affects cell motility, a wound healing assay was carried out using A-498 and 769-P cells. Cell motility was significantly decreased in si-ROCK-1 transfectants compared with control cells (Figure 5C).

**Table 1** The miR-584 expression and ROCK-1 IHC score in clinical sample

| No. | miR-584 expression level | ROCK-1 IHC score | Grade | pT |
|-----|--------------------------|------------------|-------|----|
| 1   | 2.7703                   | 0                | 3     | pT2 |
| 2   | 2.7218                   | 1                | 2     | pT1b|
| 3   | 1.6948                   | 1                | 1     | pT1b|
| 4   | 1.5945                   | 0                | 2     | pT1b|
| 5   | 1.5578                   | 1                | 2     | pT2 |
| 6   | 0.7740                   | 1                | 2     | pT1b|
| 7   | 0.6613                   | 2                | 2     | pT2 |
| 8   | 0.5520                   | 2                | 3     | pT1b|
| 9   | 0.5352                   | 1                | 2     | pT1a|
| 10  | 0.3918                   | 1                | 2     | pT1a|
| 11  | 0.2910                   | 2                | 3     | pT1a|
| 12  | 0.1592                   | 1                | 2     | pT1a|
| 13  | 0.1295                   | 1                | 3     | pT2 |
| 14  | 0.0671                   | 0                | 2     | pT1b|

Abbreviations: IHC = immunohistochemistry; RCC = renal cell carcinoma. The miR-584 expression level was compared between RCC and adjacent noncancerous (normal) tissues. The miR-584 expression was normalised to RNU48. The expression level in normal tissues is normalized as 1.

expression was also normalised to RNU48. Data are presented as mean value ± s.d. for three independent experiments and compared with the level of miR-584 in HK-2 cells normalised as 1. (B) MiR-584 expression levels were detected by using RT-PCR at 72 h after transfection. Data are presented as the mean value ± s.d. for three independent experiments compared with the level of miR-584 obtained in miR control-transfected cells that is normalised to 1. (C) Cell viability was analysed by the MTS assay 6 days after transient transfection.

**Figure 1** Expression of miR-584 in RCC cell lines and primary human tissues. (A) The HK-2 and RCC cell lines (A498 and 769-P). The miR-584 expression was normalised to RNU48. Data are presented as mean value ± s.d. for three independent experiments and compared with the level of miR-584 in HK-2 cells normalised as 1. (B) MiR-584 expression levels were detected by using RT-PCR at 72 h after transfection. Data are presented as the mean value ± s.d. for three independent experiments compared with the level of miR-584 obtained in miR control-transfected cells that is normalised to 1. (C) Cell viability was analysed by the MTS assay 6 days after transient transfection.

We also used miR microarray service to compare miR expression levels between normal kidney cell line (HK-2) and renal cancer cell lines (A-498). On the basis of the miR microarray data (not shown), we chose miR-584 as a new potential tumour suppressor candidate miR as it was significantly downregulated in kidney cancer cells and there are no reports regarding the role of miR-584 in RCC. We also performed RT-PCR using HK-2 and A-498 cells and clinical samples (renal cancer and matched normal kidney tissues) to validate the microarray data and found that miR-584 expression level was significantly lower in renal cancer cell line (A-498) compared with normal kidney cell line (HK-2). As expected from the cell line data, miR-584 expression level was also significantly lower in primary ccRCC tissues than in matched normal kidney tissues (n = 14). It has been reported that the expression level of miR-584 in malignant mesothelioma was higher compared with normal mesothelium, but functional analysis was not performed in that report (Gueld et al, 2009). So far there have been no reports regarding miR-584 in other cancers, including renal cancer.

On the basis if these results and the previous report, we hypothesised that miR-584 may have an important role as a tumour suppressor in kidney cancer. To test this hypothesis, we performed functional analyses (MTS, invasion, migration, apoptosis, and cell cycle) to look at miR-584 function using miR-584-transfected cells. As expected, miR-584 over-expression inhibited cell proliferation in renal cancer cells (A-498 and 769-P). Cell invasion and motility were also dramatically decreased after miR-584 transfection. These results suggest that miR-584 may function as a tumour suppressor and have an important role in the inhibition of invasion and migration of renal cancer cells. Therefore, we looked for invasion-related genes as potential target oncogenes of miR-584. Initially, we did microarray profiling to compare mRNA expression between miR-584 transfectants and control cells. We also used microRNA org. to identify target oncogenes of miR-584. Among candidate
target oncogenes, we found that ROCK-1 mRNA and protein expression were significantly downregulated in miR-584-transfected A-498 cells. To confirm specific binding of miR-584 to ROCK-1 mRNA, a 3′UTR luciferase assay was performed. These results show that luciferase activity was decreased after co-transfection of miR-584 and a 3′UTR vector containing the ROCK-1 miR-584 target sequence. These results show that ROCK-1 is a direct target of miR-584.

To validate whether miR-584 has a tumour suppressive role through ROCK-1 knockdown, we knocked down ROCK-1 in A-498 and 769-P cells using a si-RNA technique and did functional analysis with these cells. ROCK-1 mRNA and protein expression were significantly downregulated in miR-584-transfected A-498 cells. To confirm specific binding of miR-584 to ROCK-1 mRNA, a 3′UTR luciferase assay was performed. These results show that luciferase activity was decreased after co-transfection of miR-584 and a 3′UTR vector containing the ROCK-1 miR-584 target sequence. These results show that ROCK-1 is a direct target of miR-584.
were downregulated in A-498 and 769-P cells after si-ROCK-1 transfection. To analyze cell motility, wound healing assay was carried out and cell motility was decreased in both A-498 and 769-P cells transfected with ROCK-1 siRNA. These results are the first to demonstrate that ROCK-1 regulates cell motility in RCC.

---

Figure 4  Expression of ROCK-1 in primary clear renal cancer tissues. (A) Representative immunostaining of ROCK-1 in primary tissue samples. Picture on the left shows negative expression, right shows strongly positive expression. (B) Summary of immunostaining scores. (C) The ROCK-1 expression in primary ccRCC tissues was compared between cases with higher miR-584 expression and those with lower miR-584 expression.

Figure 5  Functional effects of ROCK-1 knockdown on A-498 and 769-P cells. (A) Expression of ROCK-1 mRNA. si-ROCK-1 or si-NC were transfected into A-498 and 769-P cells. At 48h after transfection, ROCK-1 mRNA was analysed using RT-PCR. ROCK-1 expression was normalised to β-actin. (B) ROCK-1 protein levels. At 72h after transfection, total protein was extracted and analysed by western blots. β-actin was used as a loading control. (C) Wound healing assay of si-ROCK-1 transfectants. si-ROCK-1 or si-NC was transfected into A-498 and 769-P cells. At 48h after transfection, cells were transferred from 6-well to 12-well plates and further incubated for 24h. A wound was then formed by scraping and measured after 24h.
We also investigated the relationship between miR-584 and ROCK-1 expression levels in renal cancer tissues (n = 14). We observed that ROCK-1 protein expression was significantly higher in ccRCC cases with low miR-584 expression than in those with high miR-584 expression. However, no association was found between miR-584 expression/ROCK-1 IHC score and clinicopathological factors. Thus, our data show an inverse relationship between ROCK-1 and miR-584 expression levels.

It has been reported that ROCK-1 is over-expressed in brain tumour (Oellers et al, 2009) and related to metastasis in rat MM1 hepatoma cells, bladder, lung and prostate cancer (Itoh et al, 1999; Kamai et al, 2003; Chen et al, 2008; Lin et al, 2008). ROCK-1, which is activated by activated RhoA, promotes cell invasion and motility in prostate cancer and colorectal carcinoma cells (Wilkinson et al, 2005; Lin et al, 2008). Regarding the relationship between RhoA, B, C and Rock-1 in renal cancer, Abe et al (Abe et al, 2008) has reported that the RhoC and ROCK-1 mRNA expression levels are related to progression in ccRCC. RhoB, RhoC and ROCK-1 mRNA levels were significantly higher in ccRCC tissues compared with non-cancer tissues. However, RhoA mRNA expression was similar in ccRCC and non-cancer tissues (Abe et al, 2008). Although tumour grade and stage were related to RhoC and ROCK-1 in ccRCC, they were not related to RhoB. Expression of RhoC and ROCK-1 mRNA was highly correlated with High RhoC and ccRCC, they were not related to RhoB. Expression of RhoC in ccRCC and non-cancer tissues (Abe et al, 2008). Though these studies are interesting, the exact molecular relationship between RhoC and ROCK-1 in RCC is unclear because ROCK-1 is generally activated by RhoA (Fujisawa et al, 1996; Ishizaki et al, 1996). Our data shows that the expression level of miR-584 is inversely correlated with that of ROCK-1. Given that the high expression level of ROCK-1 in RCC was shown to be associated with shorter survival (Abe et al, 2008), our present findings that ROCK-1 is a target gene of miR-584, the expression level of miR-584 may be correlated with survival and be involved in ccRCC progression. In conclusion, this is the first report to show that miR-584 functions as a tumour suppressor, directly targets oncogene ROCK-1 and decreases cell motility in RCC cells; we have also shown that miR-584 and ROCK-1 expressions are inversely correlated in primary ccRCC tissues. The limitation of this study is the small number of samples. Therefore, additional studies will be required to define the molecular mechanisms involved in the regulation of ROCK-1 by the Rho family.

ACKNOWLEDGEMENTS

We thank Dr Roger Erickson for his support and assistance with the preparation of the manuscript. This study was supported by Grants R01CA130860, R01CA138642, R01CA111470, R01CA154374, T32DK007790 from the NIH, VA Research Enhancement Award Program (REAP), and Merit Review grants.

REFERENCES

Abe H, Kamai T, Tsuji T, Nakamura F, Mashidori T, Mizuno T, Tanaka M, Tatsumiya K, Furuya N, Masuda A, Yamanishi T, Yoshida K (2008) Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 29: 155 – 161
Berezhkov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E (2005) Phylogetic shadowing and computational identification of human microRNA genes. Cell 120: 21 – 24
Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al (2005) Genome Science Group (Genome Network Project Core Group (2005) FANTOM Consortium, RIKEN Genome Exploration Research Group and Ueda HR, van Nimwegen E, Nishikawa S, Nori F, Okazaki Y, Orlando V, Pang KC, Pavan Kitamura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld Ringwald M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, WJ, Pavesi G, Pesole G, Petrovsky N, Piazza S, Reed JF, Ring BZ, Jung K, Kristiansen G (2009) MicroRNA profiling of clear cell renal cell carcinoma. J Urol 183: 743 – 751
Esquela-Kerscher A, Slack FJ (2006) Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 6: 259 – 269
Fujisawa K, Fujita A, Ishizaki T, Saito Y, Narumiya S (1996) Identification of the Rho-binding domain of p160ROCK, a Rho-associated coiled-coil containing protein kinase. J Biol Chem 271: 23022 – 23028
Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Groce CM, Baffa R (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 35: 387 – 392
Gueld M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuttila S (2009) CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma - A miRNA microarray analysis. Genes Chromosomes Cancer 48: 615 – 623
Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C, Zhang L (2009) Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 35: 1119 – 1123
Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Kondo S, Konno H, Narumiya S (1996). The small GTP-binding protein Rho binds to and activates a 160kDa Ser/Thr protein kinase homologous to myotonic dystrophy protein kinase. EMBO J 15: 1885 – 1893
Itoh K, Yoshioa K, Akede H, Uehata M, Ishizaki T, Narumiya S (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5: 221 – 225
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71 – 96
Juan D, Alexe A, Antes T, Liu H, Madabhushi A, Delisi C, Gaines S, Bhagot G, Liu OS (2010) Identification of a microRNA panel for clear-cell kidney cancer. Urology 75: 835 – 841
Jung M, Mollenkopf H, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, Nietfeld W, Rudel T, Jung K, Kristiansen G (2009) MicroRNA profiling of clear cell renal cell cancer
cancer identifies a robust signature to define renal malignancy. *J Cell Mol Med* 13: 3918– 3928
Kamai T, Arai K, Sumi S, Tsujii T, Honda M, Yamanishi T, Yoshida KI (2002) The rho/rho-kinase pathway is involved in the progression of testicular germ cell tumour. *BJU Int* 89: 449– 453
Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H (2003) Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. *Clin Cancer Res* 9: 2632– 2641
Lin SL, Chiang A, Chang D, Ying SY (2008) Loss of miR-146a function in hormone-refractory prostate cancer. *RNA* 14: 417– 424
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. *Nature* 438: 834– 838
McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. *Nat Rev Genet* 3: 737– 747
Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M (2008) Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. *J Pathol* 216: 418– 427
Oellers P, Schröer U, Senner V, Paulus W, Thanos S (2009) ROCKs are expressed in brain tumors and are required for glioma-cell migration on myelinated axons. *Glia* 57: 499– 509
Pascual D, Borque A (2008) Epidemiology of kidney cancer. *Adv Urol* 782381
Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT (2009) MicroRNA profiling of human kidney cancer subtypes. *Int J Oncol* 35: 109– 114
Reeves DJ, Liu CY (2009) Treatment of metastatic renal cell carcinoma. *Cancer Chemother Pharmacol* 64: 11– 25
Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, Kren L, Michalek J, Vyzula R (2010) Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. *J Exp Clin Cancer Res* 29: 90
Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller Jr WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drakkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. *Cancer* 116: 1272– 1280
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Puerim RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negri M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 103: 2257– 2261
Weng L, Wu X, Gao H, Mu B, Li X, Wang JH, Guo C, Jin JM, Chen Z, Covarrubias M, Yuan YC, Weiss LM, Wu H (2010) MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. *J Pathol* 222: 41– 51
Wilkinson S, Paterson HF, Marshall CJ (2005) Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. *Nat Cell Biol* 7: 255– 261
Ying SY, Chang DC, Lin SL (2008) The microRNA (miRNA): overview of the RNA genes that modulate gene function. *Mol Biotechnol* 38: 257– 268